Fidelity Freedom 2065 Fund Q4 2024 Review
2025-03-18 08:00:00 ET
Summary
- The fourth quarter of 2024 was volatile for most asset classes against a backdrop of the U.S. election, surging dollar strength, sticky inflation and rising interest rates in some markets.
- Active asset allocation decisions detracted from the Fund's performance versus the Fidelity Freedom® 2030 Composite Index in Q4, whereas the investment performance of the underlying portfolios contributed.
- Most underlying building-block portfolios across all asset classes outperformed or performed roughly in-line with their respective benchmark for the quarter.
- Active risk relative to the Composite index is at the low end of our historical range. The Fund is overweight equities, with a preference for non-U.S. relative to U.S. equities.
Performance Summary
| Cumulative | Annualized | |||||
| 3 | 1 | 3 | 5 | 10 Year/ LOF1 | ||
| Month | YTD | Year | Year | Year | ||
| Fidelity Freedom 2065 Fund Gross Expense Ratio: 0.76%2 | -2.38% | 14.02% | 14.02% | 3.95% | 9.09% | 9.94% |
| S&P 500 Index | 2.41% | 25.02% | 25.02% | 8.94% | 14.53% | 15.27% |
| Fidelity Freedom 2065 Composite Index | -1.87% | 14.40% | 14.40% | 3.99% | 8.77% | 9.58% |
| Morningstar Fund Target-Date 2065+ | -1.85% | 14.48% | 14.48% | 4.15% | 8.90% | -- |
| % Rank in Morningstar Category (1% = Best) | -- | -- | 69% | 55% | 40% | -- |
| # of Funds in Morningstar Category | -- | -- | 193 | 147 | 43 | -- |
Read the full article on Seeking Alpha
For further details see:
Fidelity Freedom 2065 Fund Q4 2024 ReviewNASDAQ: CVS
CVS Trading
-2.04% G/L:
$75.86 Last:
1,964,123 Volume:
$76 Open:



